Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Interest Coverage Ratio (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Interest Coverage Ratio for 8 consecutive years, with 10.26 as the latest value for Q3 2023.

  • On a quarterly basis, Interest Coverage Ratio fell 414.76% to 10.26 in Q3 2023 year-over-year; TTM through Jun 2024 was 38.48, a 158.84% decrease, with the full-year FY2023 number at 30.5, down 735.96% from a year prior.
  • Interest Coverage Ratio was 10.26 for Q3 2023 at Cartesian Therapeutics, up from 24.78 in the prior quarter.
  • In the past five years, Interest Coverage Ratio ranged from a high of 19.38 in Q2 2022 to a low of 79.84 in Q2 2020.
  • A 5-year average of 19.9 and a median of 11.08 in 2020 define the central range for Interest Coverage Ratio.
  • Peak YoY movement for Interest Coverage Ratio: skyrocketed 2949.22% in 2022, then plummeted 414.76% in 2023.
  • Cartesian Therapeutics' Interest Coverage Ratio stood at 37.52 in 2019, then surged by 70.48% to 11.08 in 2020, then skyrocketed by 151.78% to 5.74 in 2021, then tumbled by 283.55% to 10.53 in 2022, then rose by 2.51% to 10.26 in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Interest Coverage Ratio are 10.26 (Q3 2023), 24.78 (Q2 2023), and 22.75 (Q1 2023).